Pharmacogenetic relevance of MTHFR polymorphisms.

The 5,10-methylenetetrahydrofolate reductase (MTHFR) is a key enzyme for intracellular folate homeostasis and metabolism. Two common MTHFR polymorphisms, C677T and A1298C, which lead to an altered amino acid sequence, have been associated with a decreased enzyme activity and susceptibility to cancer suggesting that these genetic variants may modulate the risk of several malignancies. C667T, and to a lesser extent A1298C polymorphisms, are also reported to influence the cytotoxic effect of fluoropyrimidines and antifolates providing support for their pharmacogenetic role in predicting the efficacy and the toxicity in cancer and rheumatoid arthritis patients. A combined polymorphisms and haplotype analysis may result in a more effective approach than a single polymorphism one. Moreover gene-nutrient/environmental and gene-racial/ethnic interactions have been shown to affect the impact of these MTHFR genetic variants. Further well-designed studies are needed to clarify the role of MTHFR polymorphisms to derive dose adjustment recommendations on the basis of the patient's genotype.

[1]  E. Gamelin,et al.  The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer , 2008, The Pharmacogenomics Journal.

[2]  V. Catalano,et al.  Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy , 2008, The Pharmacogenomics Journal.

[3]  U. Hofmann,et al.  Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Sharon Marsh,et al.  Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. , 2008, The Journal of rheumatology.

[5]  T. Naoe,et al.  Decreased risk of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with the 5,10-methylenetetrahydrofolate reductase 677TT genotype , 2008, International journal of hematology.

[6]  S. Clarke,et al.  Thymidylate Synthase and Methylenetetrahydrofolate Reductase Gene Polymorphisms and Toxicity to Capecitabine in Advanced Colorectal Cancer Patients , 2008, Clinical Cancer Research.

[7]  Hongbing Shen,et al.  Meta- and pooled analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and gastric cancer risk: a huge-GSEC review. , 2007, American journal of epidemiology.

[8]  P. Chiusolo,et al.  MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients. , 2007, Leukemia research.

[9]  Krzysztof Safranow,et al.  677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. , 2007, Pharmacogenomics.

[10]  N. Kröger,et al.  Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. , 2007, Anticancer research.

[11]  N. Rothman,et al.  One-carbon metabolism gene polymorphisms and risk of non-Hodgkin lymphoma in Australia , 2007, Human Genetics.

[12]  Shelly C. Lu,et al.  Genetic polymorphisms in the methylenetetrahydrofolate reductase and thymidylate synthase genes and risk of hepatocellular carcinoma , 2007, Hepatology.

[13]  D. Lu,et al.  A meta-analysis of association between C677T polymorphism in the methylenetetrahydrofolate reductase gene and hypertension , 2007, European Journal of Human Genetics.

[14]  C. Lewis,et al.  Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. , 2007, The Journal of investigative dermatology.

[15]  K. Matsuo,et al.  Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. , 2007, Carcinogenesis.

[16]  V. Catalano,et al.  Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Tognazzo,et al.  Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival. , 2007, Haematologica.

[18]  R. Houlston,et al.  MTHFR C677T and colorectal cancer risk: A meta‐analysis of 25 populations , 2006, International journal of cancer.

[19]  Simon Gilbody,et al.  Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. , 2006, American journal of epidemiology.

[20]  M. Mochizuki,et al.  Pharmacogenetic study of methylenetetrahydrofolate reductase and thymidylate synthase in Japanese and assessment of ethnic and gender differences. , 2007, Pharmacogenomics.

[21]  R. Scott,et al.  Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks , 2007, Breast Cancer Research and Treatment.

[22]  S. Vollset,et al.  Functional inference of the methylenetetrahydrofolate reductase 677 C > T and 1298A > C polymorphisms from a large-scale epidemiological study , 2007, Human Genetics.

[23]  B. Bonanni,et al.  Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis , 2007, Breast Cancer Research and Treatment.

[24]  Y. Huang,et al.  Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: a meta-analysis , 2006, Journal of Human Genetics.

[25]  S. Park,et al.  Polymorphisms of the methylenetetrahydrofolate reductase gene and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation , 2006, Annals of Hematology.

[26]  J. Kremer,et al.  Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[27]  S. Larsson,et al.  Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. , 2006, Gastroenterology.

[28]  C. Ulrich,et al.  Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  J. Ajani,et al.  Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Giannouli,et al.  A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia , 2006, European Journal of Epidemiology.

[31]  A. El-Sohemy,et al.  Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. , 2006, The Journal of rheumatology.

[32]  G. Watanabe,et al.  Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Judith A M Wessels,et al.  Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. , 2006, Arthritis and rheumatism.

[34]  J. McCluskey,et al.  Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate , 2006, Bone Marrow Transplantation.

[35]  J. Potter,et al.  Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation , 2006, Bone Marrow Transplantation.

[36]  J. Kremer,et al.  Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. , 2006, Arthritis and rheumatism.

[37]  V. Torri,et al.  Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at‐risk Italian population , 2006, International journal of cancer.

[38]  T. Beasley,et al.  Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[39]  D. Jewell,et al.  The pharmacogenetics of methotrexate in inflammatory bowel disease , 2005 .

[40]  A. Parle‐McDermott,et al.  Screening for new MTHFR polymorphisms and NTD risk , 2005, American journal of medical genetics. Part A.

[41]  G. Horneff,et al.  Influence of methylenetetrahydrofolate reductase polymorphisms on efficacy and toxicity of methotrexate in patients with juvenile idiopathic arthritis. , 2005, The Journal of rheumatology.

[42]  N. Rothman,et al.  Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. , 2005, Lung cancer.

[43]  Hongbing Shen,et al.  Methylenetetrahydrofolate reductase polymorphisms and risk of squamous cell carcinoma of the head and neck: A case‐control analysis , 2005, International journal of cancer.

[44]  T. Rebbeck,et al.  Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. , 2005, Cancer research.

[45]  A. Jakobsen,et al.  Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphism in normal tissue as predictors of fluorouracil sensitivity. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  R. Clarke,et al.  Homocysteine, MTHFR and risk of venous thrombosis: a meta‐analysis of published epidemiological studies , 2005, Journal of thrombosis and haemostasis : JTH.

[47]  Hongbing Shen,et al.  Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China. , 2005, Oncology reports.

[48]  T. Niu,et al.  A Common Haplotype on Methylenetetrahydrofolate Reductase Gene Modifies the Effect of Angiotensin-Converting Enzyme Inhibitor on Blood Pressure in Essential Hypertension Patients—A Family-Based Association Study , 2005, Clinical and experimental hypertension.

[49]  N. Magné,et al.  Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients. , 2004, Pharmacogenetics.

[50]  C. Ulrich,et al.  Methylenetetrahydrofolate Reductase Genotype Affects Risk of Relapse after Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia , 2004, Clinical Cancer Research.

[51]  H. McLeod,et al.  Single nucleotide polymorphism profiling across the methotrexate pathway in normal subjects and patients with rheumatoid arthritis. , 2004, Pharmacogenomics.

[52]  D. Mevorach,et al.  Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene , 2004, Annals of the rheumatic diseases.

[53]  M. Spitz,et al.  Polymorphisms of folate metabolic genes and susceptibility to bladder cancer: a case-control study. , 2004, Carcinogenesis.

[54]  J. Ioannidis,et al.  Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis , 2004, Journal of hypertension.

[55]  C. Ulrich,et al.  Predictors of oral mucositis in patients receiving hematopoietic cell transplants for chronic myelogenous leukemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  C. Thorn,et al.  Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer. , 2004, European journal of cancer.

[57]  M. Lucock,et al.  Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. , 2004, Journal of the National Cancer Institute.

[58]  P. Laurent-Puig,et al.  Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity , 2004, British Journal of Cancer.

[59]  R. Rozen,et al.  Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[60]  F. Innocenti,et al.  Effect of methylenetetrahydrofolate reductase 677C→T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients , 2003, International journal of cancer.

[61]  S. Ogino,et al.  Genotype and haplotype distributions of MTHFR 677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis , 2003, Journal of Human Genetics.

[62]  L. Mele,et al.  Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[63]  Petra Verhoef,et al.  MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. , 2002, JAMA.

[64]  N. Sakura,et al.  The C677T mutation in the methylenetetrahydrofolate reductase gene contributes to hyperhomocysteinemia in patients taking anticonvulsants , 2002, Brain and Development.

[65]  D. Girelli,et al.  A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[66]  A. Taniguchi,et al.  Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. , 2002, Pharmacogenetics.

[67]  H. Blom,et al.  The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. , 2001, Arthritis and rheumatism.

[68]  L. Kluijtmans,et al.  Phase I clinical and pharmacogenetic trial of irinotecan and raltitrexed administered every 21 days to patients with cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  R. Rozen,et al.  Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. , 2000, American journal of human genetics.

[70]  Quanhe Yang,et al.  5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. , 2000, American journal of epidemiology.

[71]  D. Crivellari,et al.  MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF) , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  J. Mills,et al.  Methylenetetrahydrofolate reductase thermolabile variant and oral clefts. , 1999, American journal of medical genetics.

[73]  C. Brown,et al.  The C677T methylenetetrahydrofolate reductase polymorphism influences the homocysteine-lowering effect of hormone replacement therapy. , 1999, Molecular genetics and metabolism.

[74]  G. Shaw,et al.  Analysis of select folate pathway genes, PAX3, and human T in a Midwestern neural tube defect population. , 1999, Teratology.

[75]  F. Gabreëls,et al.  A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? , 1998, American journal of human genetics.

[76]  S. Tonstad,et al.  The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine. , 1998, The Journal of pediatrics.

[77]  M. Esteller,et al.  Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. , 1997, Carcinogenesis.

[78]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.